Africa IVD Market Size, Share, Forecast, & Trends Analysis by Offering, Technology (Immunoassay, PoC, Molecular Diagnostics, Coagulation) Application (Infectious Diseases, Diabetes, Oncology) Diagnostic Approach (Lab, OTC, PoCT) End User- Forecast to 2031

Africa IVD Market Size, Share, Forecast, & Trends Analysis by Offering, Technology (Immunoassay, PoC, Molecular Diagnostics, Coagulation) Application (Infectious Diseases, Diabetes, Oncology) Diagnostic Approach (Lab, OTC, PoCT) End User- Forecast to 2031

The Africa IVD market is expected to reach $1.65 billion by 2031, at a CAGR of 3.1% from 2024 to 2031.

With extensive primary and secondary research and in-depth analysis of the market scenario, the report studies the key industry drivers, restraints, challenges, and opportunities. The growth of this market is driven by the rising prevalence of chronic & infectious diseases, IVD market players’ increasing investments in Africa, the growing demand for Point-of-care (POC) & rapid diagnostics, the rising geriatric population, government initiatives supporting Africa's healthcare sector, rising healthcare expenditure, and increasing R&D expenditure. However, the high prices of advanced IVD products, result variations observed in rapid IVD tests, and stringent technical requirements & regulatory processes for high/moderate-complexity tests restrain the growth of this market.

Furthermore, increasing awareness regarding the importance of early diagnosis, advances in genomics & proteomics, and the increasing adoption of personalized medicine are expected to generate growth opportunities for market stakeholders. However, uneven access to healthcare and the shortage of trained healthcare professionals are major challenges in the Africa IVD market.

Based on offering, the Africa IVD market is segmented into reagents & kits, instruments, and software & services. The kits & reagents segment is projected to witness the highest growth rate of 3.3% during the forecast period of 2024–2031. The growth of this segment is driven by the emerging threats of infectious diseases such as malaria, tuberculosis, and other neglected tropical diseases, increasing test volumes for infectious diseases, and favorable initiatives to improve diagnosis, treatment, and healthcare access.

Based on technology, the Africa IVD market is segmented into immunoassay/immunochemistry, whole blood glucose monitoring, molecular diagnostics, point-of-care diagnostics, biochemistry/clinical chemistry, microbiology, hematology, coagulation & hemostasis, and other IVD technologies. In 2024, the immunoassay/immunochemistry segment is expected to account for the largest share of 34.5% of the Africa IVD market. The segment’s large share is attributed to the benefits of immunoassay technologies, such as efficient, convenient, and accurate research tools for the detection and quantitation of targets, continuous development of new biomarkers, and cost-effectiveness, coupled with the growing adoption of automated platforms for ELISA.

Based on application, the Africa IVD market is segmented into infectious diseases, diabetes, oncology, cardiology, nephrology, autoimmune diseases, and other applications. The cardiology segment is expected to grow at the highest CAGR during the forecast period of 2024 to 2031. The growing cardiac disease burden, coupled with advancements in cardiac disease diagnostic testing and the growing awareness of point-of-care and rapid cardiac tests among healthcare providers, including physicians and cardiologists, is expected to drive the segment’s growth.

Risk factors such as hypertension, diabetes mellitus, obesity, and dyslipidemia are increasingly prevalent in African countries, significantly contributing to the rising cases of CVDs. Therefore, the prevalence of cardiovascular diseases is on the rise in the African region. The American Heart Association estimates that cardiovascular diseases will overtake infectious diseases as the leading cause of death in the African continent by the year 2030.

Based on diagnostic approach, the Africa IVD market is categorized into laboratory testing, point-of-care testing, and OTC/self-testing. The point-of-care testing segment is expected to grow at a faster CAGR during the forecast period. The segment’s growth can be attributed to the affordability, ease of use, and rapid results offered by the POCT, high burden of hepatitis, syphilis, and HIV coupled with POCT as the preferred option for testing these diseases, and favorable initiatives to expand the access of POCT in the region.

In Africa, the adoption of POCT is driven by its affordability, ease of use, and quick results. The region's economic and infrastructural challenges, coupled with underdeveloped testing capabilities, further underscore the importance of POCT. It is commonly used for diagnosing hepatitis, syphilis, and HIV. The rising prevalence of HIV, particularly among young women and adolescent girls in sub-Saharan Africa—who accounted for over 77% of new infections among young people aged 15-24 in 2022, according to UNAIDS—is expected to increase the demand for POCT.

Based on end user, the Africa IVD market is segmented into diagnostic laboratories, hospitals & clinics, home healthcare, and other end users, which include nursing homes, academic & research institutes, ambulatory care centers, and transfusion laboratories. The hospitals & clinics segment is expected to grow at the highest CAGR during the forecast period of 2024 to 2031. With the frequent outbreaks of infectious diseases and the increasing prevalence of chronic diseases, the number of hospital visits is expected to increase, which is expected to support the segment's growth in the future. African countries are also significantly investing in hospital infrastructure to treat patients from across the world. For instance, in February 2024, Roha Medical Campus, backed by U.S. investors, invested USD 400 million to open a hospital complex, which is expected to be operational in 2025. Such initiatives, coupled with the rising prevalence of diseases, growing number of hospitals, and rising demand for diagnostic testing, drive the segment growth.

An in-depth analysis of the geographical scenario of the Africa IVD market provides detailed qualitative and quantitative insights into countries of Africa: South Africa, Egypt, Algeria, Nigeria, Morocco, Egypt, Kenya, Tunisia, Côte d’Ivoire, Tanzania, Cameroon, Ret of Africa. In 2024, South Africa is expected to dominate the Africa IVD market.

There is a high prevalence of communicable and non-communicable diseases in South Africa. According to Our World in Data (Global Change Data Lab, U.K.), the total burden of neglected tropical diseases and malaria (measured in Disability-Adjusted Life Years (DALYs) in South Africa was expected to reach 135,889.7 in 2021. Furthermore, according to UNAIDS DATA 2021, 7.8 million people were living with HIV in South Africa, an increase of 3.0% from 2010. The high healthcare expenditure, growing access to quality healthcare, favorable government initiatives, and presence of distributors for major IVD companies improving access to IVD products in the country.

Some of the key players operating in the Africa IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc., (U.S.), Illumina, Inc. (U.S.), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China).

Scope of the Report:

Africa IVD Market Assessment by Offering

Reagents & Kits
Instruments
Software & Services

Africa IVD Market Assessment By Technology

Immunoassay/Immunochemistry
Whole Blood Glucose Monitoring
Molecular Diagnostics
Point-of-care Diagnostics
Biochemistry/Clinical Chemistry
Microbiology
Hematology
Coagulation & Hemostasis
Other IVD Technologies

(Other IVD Technologies include hybridization and loop-mediated amplification)

Africa IVD Market Assessment by Application

infectious diseases
diabetes
Oncology
Cardiology
Nephrology
Autoimmune Diseases
Other Applications

(Other applications include toxicology, gastroenterology, neonatal, genetic, and neurological disorders)

Africa IVD Market Assessment by Diagnostic Approach

Diagnostic Laboratories
Point-of-care Testing
OTC/Self-testing Africa IVD Market Assessment by End User
Laboratory Testing
Hospitals & Clinics
Home Healthcare
Other End Users

(Other End Users segment includes long-term care facilities, academic & research institutes, ambulatory care centers, and transfusion laboratories)

Africa IVD Market Assessment, by Geography

South Africa
Egypt
Algeria
Nigeria
Morocco
Kenya
Tunisia
Côte d’Ivoire
Tanzania
Cameroon
Rest of Africa

Africa IVD Market] Report Summary

Report Metrics	Details
Years Considered	2022 - 2031
Base Year	2023
Forecast Period	2024-2031
Page Count	242
Units Referenced	Value (USD Million)
Segments/Key Topics	Offering, Technology, Application, Diagnostic Approach, End User
Regions Covered	South Africa, Egypt, Algeria, Nigeria, Morocco, Kenya, Tunisia, Côte d’Ivoire, Tanzania, Cameroon, Rest of Africa
Key Companies Mentioned	Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc., (U.S.), Illumina, Inc. (U.S.), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China)

FAQs About the Report

What is the focus of the Africa IVD market?

The Africa IVD market covers the market sizes & forecasts by offering, technology, application, diagnostic approach, and end user. The Africa IVD market studied in this report involves the value analysis of various segments and sub-segments of the Africa IVD market at regional and country levels.

What is the value of revenue generated from the sale of IVD products in Africa? At what rate is their demand expected to grow for the next 5-7 years?

The Africa IVD market is projected to reach $1.65 billion by 2031, at a CAGR of 3.1% during the forecast period.

Which offering segment held the major share of the market in 2024?

In 2024, the reagents & kits segment is expected to account for the largest share of the Africa IVD market.

Which technology segment held the major share of the market in 2024?

In 2024, the immunoassay/immunochemistry segment is expected to account for the largest share of the Africa IVD market.

Which application segment held the major share of the market in 2024?

In 2024, the infectious diseases segment is expected to account for the largest share of the Africa IVD market.

What are the key factors supporting the growth of this market? Also, what are the major opportunities for existing market players and new entrants in the Africa IVD market?

The Africa IVD market is driven by the rising prevalence of chronic & infectious diseases, IVD market players’ increasing investments in Africa, the growing demand for Point-of-care (POC) & rapid diagnostics, the rising geriatric population, government initiatives supporting Africa's healthcare sector, rising healthcare expenditure, and increasing R&D expenditure.

Moreover, increasing awareness regarding the importance of early diagnosis, advances in genomics & proteomics, and the increasing adoption of personalized medicine are expected to generate growth opportunities for the players operating in the Africa IVD market.

Who are the major players operating in the Africa IVD market?

The key players operating in the Africa IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc., (U.S.), Illumina, Inc. (U.S.), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China).

Which countries are likely to offer significant growth opportunities for the vendors in this market during the analysis period?

South Africa is projected to offer significant growth opportunities for the vendors in this market due to growing healthcare expenditure, growing availability due to partnerships & collaborations between diagnostic test providers & distributors, favorable government initiatives, and growing healthcare infrastructure & access in South Africa.